Clinical Trial Update: Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is an ongoing Phase 1/2 clinical trial evaluating adverse events and pharmacokinetics for intravenous Telisotuzumab Adizutecan (ABBV-400) in adults with un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ABBV-400

Snippet

Sponsor: AbbVie | Conditions: Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING